Emtora Clinical Data to be Highlighted in Podium Presentation at Prestigious 2024 Digestive Disease Week Annual Meeting
Emtora Biosciences, Inc., a privately-held, San Antonio-based biotechnology company developing a novel reformulated version of a previously-approved drug today announced the acceptance of an abstract for oral presentation at the upcoming Digestive Disease Week (“DDW”) Annual Meeting.
- Emtora Biosciences, Inc., a privately-held, San Antonio-based biotechnology company developing a novel reformulated version of a previously-approved drug today announced the acceptance of an abstract for oral presentation at the upcoming Digestive Disease Week (“DDW”) Annual Meeting.
- DDW is the world’s premier meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery, which will take place in Washington D.C. May 18-21, 2024.
- FAP is an incurable systemic disease for which no approved chemo-preventive agent exists.
- Presentation: PHASE IIA TRIAL OF ENCAPSULATED RAPAMYCIN (ERAPA) IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS TO REDUCE INTESTINAL POLYP BURDEN: 6 MONTH INTERIM RESULTS